Company Overview

Innoviva, Inc. is a healthcare-focused holding company that manages and invests in a portfolio of biopharmaceutical assets, with a primary emphasis on respiratory, infectious disease, and critical care therapies. The company does not directly commercialize products at scale; instead, its core business model centers on owning, managing, and monetizing royalties and equity interests in operating subsidiaries and partnered pharmaceutical products. Innoviva’s largest and most consistent revenue driver is royalty income derived from global sales of respiratory medicines developed and commercialized by GlaxoSmithKline.

The company’s royalty portfolio is anchored by long-acting inhaled respiratory therapies, including products for chronic obstructive pulmonary disease (COPD) and asthma. Innoviva’s strategic positioning lies in its asset-light structure, predictable royalty cash flows, and disciplined capital allocation approach. The company was originally formed through the separation of royalty and R&D assets from Theravance, Inc., evolving over time from a royalty-focused entity into a diversified healthcare holding company with controlling stakes in operating businesses.

Business Operations

Innoviva generates the majority of its revenue from royalties received under a long-term agreement with GlaxoSmithKline related to sales of Trelegy Ellipta, Breo Ellipta, and Anoro Ellipta, which are marketed globally for COPD and asthma. These royalties are based on net sales and represent a high-margin, recurring revenue stream with minimal operating cost exposure. The company reports its activities primarily as a single reporting segment, reflecting its holding company structure rather than traditional operating divisions.

In addition to royalty management, Innoviva controls Innoviva Specialty Therapeutics, Inc., a subsidiary focused on the commercialization and development of therapies for serious bacterial infections and critical care indications. Innoviva also owns Entasis Therapeutics Holdings Inc., an anti-infective company developing novel antibiotics for multidrug-resistant infections. Through these subsidiaries, Innoviva participates directly in clinical development, regulatory strategy, and, in limited cases, commercialization activities, primarily within the United States.

Strategic Position & Investments

Innoviva’s strategic direction emphasizes disciplined capital deployment, including reinvestment of royalty cash flows into acquisitions, internal development programs, and opportunistic share repurchases. A key strategic move was the acquisition of Entasis Therapeutics Holdings Inc., which expanded Innoviva’s presence in the anti-infective and hospital-based therapeutics market. The company has publicly stated its intention to focus on durable healthcare assets with defensible market positions and long product lifecycles.

The company continues to evaluate opportunities in respiratory medicine, infectious disease, and critical care, particularly where unmet medical needs and regulatory incentives support long-term value creation. Innoviva’s strategy balances maintaining its royalty base with selectively building operating subsidiaries that can generate independent revenue streams, while avoiding broad diversification outside healthcare.

Geographic Footprint

Innoviva is headquartered in the United States, with its principal executive offices in California. While the company’s direct operations are primarily U.S.-based, its economic exposure is global due to worldwide sales of partnered respiratory products. Royalties are generated from North America, Europe, Asia-Pacific, and other international markets where GlaxoSmithKline commercializes the relevant therapies.

Through its subsidiaries, Innoviva maintains a more limited physical footprint, with research, development, and corporate functions concentrated in the United States. International influence is largely indirect, stemming from global product commercialization by partners rather than Innoviva-operated facilities or sales organizations.

Leadership & Governance

Innoviva is led by an executive team with a strong focus on capital allocation, asset management, and long-term shareholder value. Leadership emphasizes financial discipline, active portfolio management, and a selective approach to operational expansion. The company operates under a governance framework typical of publicly traded U.S. healthcare holding companies, with oversight from an independent board of directors.

Key executives include:

• Pavel Raifeld – Chief Executive Officer
• Adam Kaye – Chief Financial Officer
• Chuck Cloutier – General Counsel and Corporate Secretary
• Andrew Green – Chief Accounting Officer

The leadership team has consistently articulated a strategy centered on maximizing the value of existing royalty assets while deploying capital into high-conviction healthcare investments that align with Innoviva’s core therapeutic focus.